Tarlatamab + durva 在维持治疗情境下显著改善 1LM ES-SCLC 的 OS、PFS 和 ORR。将讨论维持治疗与 2L tarlatamab，我们等待一线数据。无论如何，DLL3 药物确实正在改变 SCLC 的预后。 @OncoAlert @myESMO #ESMO26
97 浏览 · 6 赞 · 4 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Julien Mazieres · x.com